Clomipramine is a medication used to treat obsessive-compulsive disorder (OCD). It is the only tricyclic antidepressant with FDA approval specifically for OCD, and it remains one of the most effective drugs available for reducing obsessive thoughts and compulsive behaviors. It’s approved for adults and for children aged 10 and older.
How Clomipramine Treats OCD
Clomipramine works primarily by increasing serotonin activity in the brain. Low serotonin signaling plays a central role in OCD, and clomipramine blocks the reabsorption of serotonin more powerfully than most other tricyclic antidepressants. This is what makes it uniquely useful for OCD within its drug class.
The medication was first developed as an antidepressant, and it does still affect norepinephrine and other brain chemicals. But its strong serotonin effects are what set it apart for OCD treatment. In clinical trials that led to its approval, clomipramine was tested in two 10-week studies in adults and one 8-week study in children and adolescents aged 10 to 17, all showing meaningful reductions in obsessive-compulsive symptoms compared to placebo.
Where It Fits Among OCD Medications
Modern SSRIs (selective serotonin reuptake inhibitors) are typically prescribed first for OCD because they cause fewer side effects. However, clomipramine consistently performs well in comparisons. A systematic review and meta-analysis published in BMJ Mental Health found that clomipramine was more effective than SSRIs for OCD symptoms, even after the researchers corrected for differences in study quality and bias. The advantage held up across multiple statistical models.
That said, direct head-to-head trials between clomipramine and individual SSRIs haven’t shown as clear a gap. The stronger side effect profile of clomipramine is the main reason it’s not used first. Current psychiatric guidelines recommend trying one or two SSRIs before moving to clomipramine. For people whose OCD hasn’t responded adequately to those first-line options, clomipramine is a well-established next step.
Off-Label Uses
While OCD is the only FDA-approved indication, doctors sometimes prescribe clomipramine off-label for other conditions. These include panic disorder, depression that hasn’t responded to other treatments, chronic pain syndromes, and certain anxiety disorders. Its broad effects on serotonin and norepinephrine make it useful in situations where newer, more targeted medications haven’t worked. Off-label use is common in psychiatry, but the strongest evidence for clomipramine is in OCD.
What to Expect During Treatment
Clomipramine doesn’t work quickly. Clinical improvement typically takes 6 to 10 weeks to become noticeable. This can feel like a long wait, especially when OCD symptoms are severe, but it’s important to give the medication adequate time before concluding it isn’t helping.
Treatment starts at a low dose of 25 mg per day, usually taken at bedtime. Over the first two weeks, the dose is gradually increased to around 100 mg daily, split across meals to reduce stomach upset. After that initial period, the dose can continue to climb over several weeks. Adults can go up to a maximum of 250 mg per day. For children and adolescents, the ceiling is 200 mg per day or 3 mg per kilogram of body weight, whichever is lower.
The slow ramp-up isn’t optional. Starting too high or increasing too fast raises the risk of side effects significantly. Most people find a dose somewhere in the 100 to 250 mg range where symptoms improve without side effects becoming intolerable.
Common Side Effects
Clomipramine’s side effect profile is broader than what most people experience with SSRIs. The most frequent complaints stem from its effects on a brain chemical called acetylcholine. These include dry mouth, constipation, blurred vision, drowsiness, dizziness, and difficulty urinating. Many of these are worst in the first few weeks and gradually improve as your body adjusts.
Weight gain and sexual side effects (reduced desire, difficulty with orgasm) are also common and tend to persist for as long as you take the medication. Drowsiness is why bedtime dosing is standard, though some people still feel groggy during the day, particularly at higher doses.
Serious Risks to Be Aware Of
Clomipramine lowers the seizure threshold, meaning it makes seizures more likely, particularly at higher doses. This risk is one reason the maximum dose is capped at 250 mg. People with a history of seizures need careful monitoring.
Heart rhythm changes are another concern. Clomipramine can prolong a specific interval in the heart’s electrical cycle (called QTc), which in rare cases leads to dangerous irregular heartbeats. Your doctor will likely check an electrocardiogram before starting treatment and possibly during dose increases.
Like all antidepressants, clomipramine carries an FDA black box warning about increased risk of suicidal thoughts in children, adolescents, and young adults under 25, particularly in the early weeks of treatment or after dose changes. This doesn’t mean the medication causes suicidal behavior in most people, but close monitoring during the initial phase is standard.
Clomipramine should never be combined with MAO inhibitors, a class of older antidepressants. The combination can trigger a life-threatening reaction called serotonin syndrome, which involves dangerously high body temperature, muscle rigidity, and rapid heart rate. A washout period of at least two weeks is required between stopping one and starting the other.
For Treatment-Resistant OCD
Clomipramine holds a particularly important role for people whose OCD hasn’t responded to standard treatments. Practice guidelines recommend it after one or two failed SSRI trials, and the effective dose range for treatment-resistant cases is typically 150 to 250 mg daily.
For the most severe, refractory cases, there is even evidence supporting intravenous clomipramine. When the drug is given directly into the bloodstream, it bypasses the liver’s initial processing, which changes the ratio of active compounds in a way that may boost effectiveness. A double-blind, placebo-controlled trial in highly treatment-resistant patients found that intravenous clomipramine, gradually increased to 250 mg, was both well-tolerated and more effective than placebo. This approach is not widely available but represents an option for people who have exhausted other strategies.